Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinmeng Liu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhancing METTL3-mediated m6A modification of Fzd3 mRNA exhibits neuroprotection in amyotrophic lateral sclerosis

    by Jinmeng Liu, Qiupeng Yan, Yingjun Guan, Chunjie Xu, Xiaonan Ma, Jingtong Zhao, Xiaosu Chen, Mu Li, Xue Zhang, Haoyun Zhang, et al.

    Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive loss of motor neurons (MNs). N 6 -methyladenosine (m 6 A) is the most abundant mRNA modification, yet its role in ALS MNs degeneration remains poorly understood. In this study we observed a significant decrease in global m 6 A levels in the spinal cords of hSOD1 G93A transgenic ALS mouse model and hSOD1 G93A NSC34 cells, accompanied by reduced expression of the methyltransferase METTL3. Knocking down Mettl3 in the ALS MN model further impaired neurite outgrowth and acetylcholine release in an m 6 A-dependent manner. AAV-mediated Mettl3 overexpression attenuated MN loss, improved motor ability and extended survival in ALS mice. Integrated analysis based on m 6 A-methylome and transcriptome identified Fzd3 , a WNT signaling pathway receptor gene, as a key m 6 A-modified target. Mechanistically, METTL3 promotes the expression of FZD3 by enhancing the stability of its mRNA through IGF2BP3. Knockdown of Fzd3 abolished the protective effects of METTL3 on neurite outgrowth and acetylcholine release in ALS MNs. Collectively, our research reveals that METTL3-mediated m 6 A modification on Fzd3 mRNA plays a critical role in ALS pathogenesis and highlights METTL3 as a promising therapeutic target for ALS.

  • Open Access

    Exploring the Role of Axons in ALS from Multiple Perspectives

    by Xiaosu Chen, Shuchang Lv, Jinmeng Liu, Yingjun Guan, Chunjie Xu, Xiaonan Ma, Mu Li, Xue Bai, Kexin Liu, Haoyun Zhang, et al.

    Amyotrophic lateral sclerosis (ALS), commonly known as motor neuron disease, is a neurodegenerative disorder characterized by the progressive degeneration of both upper and lower motor neurons. This pathological process results in muscle weakness and can culminate in paralysis. To date, the precise etiology of ALS remains unclear. However, a burgeoning body of research indicates that axonal dysfunction is a pivotal element in the pathogenesis of ALS and significantly influences the progression of disease. Dysfunction of axons in ALS can result in impediments to nerve impulse transmission, leading to motor impairment, muscle atrophy, and other associated complications that severely compromise patients’ quality of life and survival prognosis. In this review, we concentrate on several key areas: the ultrastructure of axons, the mechanisms of axonal degeneration in ALS, the impact of impaired axonal transport on disease progression in ALS, and the potential for axonal regeneration within the central nervous system (CNS). Our objective is to achieve a more holistic and profound understanding of the multifaceted role that axons play in ALS, thereby offering a more intricate and refined perspective on targeted axonal therapeutic interventions.


  • Open Access

    Induced Pluripotent Stem Cells and Their Applications in Amyotrophic Lateral Sclerosis

    by Hongmei Du, Zijun Huo, Yanchun Chen, Zhenhan Zhao, Fandi Meng, Xuemei Wang, Shiyue Liu, Haoyun Zhang, Fenghua Zhou, Jinmeng Liu, et al.

    Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that results in the loss of motor function in the central nervous system (CNS) and ultimately death. The mechanisms underlying ALS pathogenesis have not yet been fully elucidated, and ALS cannot be treated effectively. Most studies have applied animal or single-gene intervention cell lines as ALS disease models, but they cannot accurately reflect the pathological characteristics of ALS. Induced pluripotent stem cells (iPSCs) can be reprogrammed from somatic cells, possessing the ability to self-renew and differentiate into a variety of cells. iPSCs can be obtained from ALS patients with different genotypes and phenotypes, and the genetic background of the donor cells remains unchanged during reprogramming. iPSCs can differentiate into neurons and glial cells related to ALS. Therefore, iPSCs provide an excellent method to evaluate the impact of diseases on ALS patients. Moreover, patient-derived iPSCs are obtained from their own somatic cells, avoiding ethical concerns and posing only a low risk of immune rejection. The iPSC technology creates new hope for ALS treatment. Here, we review recent studies on iPSCs and their applications in disease modeling, drug screening and cell therapy in ALS, with a particular focus on the potential for ALS treatment.


  • Open Access

    The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis

    by Jiantao Zhao, Xuemei Wang, Zijun Huo, Yanchun Chen, Jinmeng Liu, Zhenhan Zhao, Fandi Meng, Qi Su, Weiwei Bao, Lingyun Zhang, et al.

    Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and highly fatal neurodegenerative disease. Although the pathogenesis of ALS remains unclear, increasing evidence suggests that a key contributing factor is mitochondrial dysfunction. Mitochondria are organelles in eukaryotic cells responsible for bioenergy production, cellular metabolism, signal transduction, calcium homeostasis, and immune responses and the stability of their function plays a crucial role in neurons. A single disorder or defect in mitochondrial function can lead to pathological changes in cells, such as an impaired calcium buffer period, excessive generation of free radicals, increased mitochondrial membrane permeability, and oxidative stress (OS). Recent research has also shown that these mitochondrial dysfunctions are also associated with pathological changes in ALS and are believed to be commonly involved in the pathogenesis of the disease. This article reviews the latest research on mitochondrial dysfunction and its impact on the progression of ALS, with specific attention to the potential of novel therapeutic strategies targeting mitochondrial dysfunction.


  • Open Access

    The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis

    by Jinmeng Liu, Fenghua Zhou, Yingjun Guan, Fandi Meng, Zhenhan Zhao, Qi Su, Weiwei Bao, Xuemei Wang, Jiantao Zhao, Zijun Huo, et al.

    Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects upper and lower motor neurons. As there is no effective treatment for ALS, it is particularly important to screen key gene therapy targets. The identifications of microRNAs (miRNAs) have completely changed the traditional view of gene regulation. miRNAs are small noncoding single-stranded RNA molecules involved in the regulation of post-transcriptional gene expression. Recent advances also indicate that miRNAs are biomarkers in many diseases, including neurodegenerative diseases. In this review, we summarize recent advances regarding the mechanisms underlying the role of miRNAs in ALS pathogenesis and its application to gene therapy for ALS. The potential of miRNAs to target diverse pathways opens a new avenue for ALS therapy.


  • Open Access

    Potential Roles of the WNT Signaling Pathway in Amyotrophic Lateral Sclerosis

    by Xin Jiang, Yingjun Guan, Zhenhan Zhao, Fandi Meng, Xuemei Wang, Xueshuai Gao, Jinmeng Liu, Yanchun Chen, Fenghua Zhou, Shuanhu Zhou, et al.

    The WNT signaling pathway plays an important role in the physiological and pathophysiological processes of the central nervous system and the neurodegenerative disease amyotrophic lateral sclerosis (ALS). We reviewed the literature pertinent to WNT/β–catenin signaling in ALS from cellular studies, animal models, and human clinical trials. WNT, WNT receptors, and other components of the WNT signaling pathway are expressed in both ALS patients and transgenic mice, and are involved in the pathogenesis of ALS. Studies have shown that abnormal activation of the WNT/β–catenin signaling pathway is related to neuronal degeneration and glial cell proliferation. WNT/Ca2+ signaling is associated with the pro–inflammatory phenotype of microglia; data on the muscle skeletal receptor Tyr kinase receptor in superoxide dismutase–1–G93A mice indicate that gene therapy is necessary for successful treatment of ALS. The varying profiles of lipoprotein receptor–related protein 4 antibodies in different ethnic groups suggest that individual treatment and multifactorial personalized approaches may be necessary for effective ALS therapy. In conclusion, the WNT signaling pathway is important to the ALS disease process, making it a likely therapeutic target.